Geographic Expansion of Oropouche Fever Into Non‐Endemic Regions of Brazil: Implications for Health Surveillance
Journal of Medical Virology · 2025-12 · 97 (12)
DOI: 10.1002/jmv.70744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 03.12.2025. Verfasst von Rafael Pedro de Souza Nascimento und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Federal University of the São Francisco Valley (UNIVASF), Petrolina, Pernambuco, Brazil. Hauptthemen laut MEDLINE: Bunyaviridae Infections, Orthobunyavirus, Epidemiological Monitoring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: C.D.F.d.S. and R.F.C. have a scientific productivity scholarship grant from CNPq..
Abstract (Originalsprache)
Oropouche fever is an arboviral disease caused by the Oropouche virus (OROV; Peribunyaviridae family), first identified in Brazil in 1960. This study aims to describe the epidemiological profile and spatio‐temporal dispersion of Oropouche fever cases across Brazil in 2024. The variables analyzed were sex, age, transmission area, macroregion, and federative unit. A simple descriptive analysis (absolute frequencies and proportions) was performed. Data were extracted from the Oropouche Fever Epidemiological Panel and the Brazilian Institute of Geography and Statistics (IBGE). The analysis revealed 13,786 reported cases (6.80/100,000 inhabitants), with a predominance of males (52.6%; n = 7247). The North region presented the highest incidence (41.60%; n = 5732; 33.03/100,000 inhabitants). Incidence peaks during early (weeks 5–6) and late 2024 (week 52) were identified, with heterogeneous regional spread reflecting a possible outbreak progression from the North to Northeast and subsequently Southeast. Espírito Santo state recorded the highest national incidence (151.60/100,000 inhabitants; 42.20% of cases; n = 5812). The expansion of OROV into non‐endemic regions highlights an emerging public health threat. Urgent, systematic measures are required to strengthen Brazil's health surveillance system, ensuring timely and effective responses to mitigate further geographic spread.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, Federal University of the São Francisco Valley (UNIVASF), Petrolina, Pernambuco, Brazil.
- Postgraduate Program in Family Health, Oswaldo Cruz Foundation (Fiocruz), Research CNPq N2, Rio de Janeiro, Brazil.
ORCID-Profile: Rafael Pedro de Souza Nascimento, Rodrigo Feliciano do Carmo
Förderung
- C.D.F.d.S. and R.F.C. have a scientific productivity scholarship grant from CNPq.
Zitieren
APA
Nascimento, R. P. S., Oliveira, P. E., Silva Junior, A. G. D., Amorim, R. O. F., Silva, C. K. D. S., Santos, D. S., Barros, L. L. A., Menezes, H. F. N., Armstrong, A. D. C., Carmo, R. F. D., & Souza, C. D. F. (2025). Geographic Expansion of Oropouche Fever Into Non‐Endemic Regions of Brazil: Implications for Health Surveillance. Journal of Medical Virology, 97(12). https://doi.org/10.1002/jmv.70744
Vancouver
Nascimento RPS, Oliveira PE, Silva Junior AGD, Amorim ROF, Silva CKDS, Santos DS, et al. Geographic Expansion of Oropouche Fever Into Non‐Endemic Regions of Brazil: Implications for Health Surveillance. Journal of Medical Virology. 2025;97(12). doi:10.1002/jmv.70744
BibTeX
@article{Nascimento2025,
author = {Nascimento, Rafael Pedro de Souza and Oliveira, Paula Esbaltar de and Silva Junior, Adeilton Gonçalves da and Amorim, Riana Oliveira Fernandes and Silva, Cleison Keulys Dos Santos and Santos, Daniela Silva and Barros, Lethícia Lohane Almeida and Menezes, Hernany Fabricio de Novaes and Armstrong, Anderson da Costa and Carmo, Rodrigo Feliciano do and Souza, Carlos Dornels Freire de},
title = {Geographic Expansion of Oropouche Fever Into Non‐Endemic Regions of Brazil: Implications for Health Surveillance},
journal = {Journal of Medical Virology},
year = {2025},
volume = {97},
number = {12},
doi = {10.1002/jmv.70744}
}
EUVIMED